Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shoenfeld, Y.
Right arrow Articles by Blank, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoenfeld, Y.
Right arrow Articles by Blank, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 14, No. 11, pp. 1303-1311, November 2002
© 2002 Japanese Society for Immunology

Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus

Yehuda Shoenfeld1, Lubica Rauova1,3, Boris Gilburd1, Filip Kvapil1, Iris Goldberg2, Jury Kopolovic2, Jozef Rovensky3 and Miri Blank1

1 Center for Autoimmune Diseases, Department of Internal Medicine B, and 2 Department of Pathology, Sheba Medical Center, Tel Hashomer 52621, Israel 3 Research Institute of Rheumatic Diseases, Piestany, Slovakia

Correspondence to: Y. Shoenfeld; E-mail: shoenfel{at}sheba.health.gov.il
Transmitting editor: I. Pecht

Since the idiotypic network is an important mechanism for controlling the immune repertoire, we tested anti-idiotypic modulation employing concentrated specific natural polyclonal anti-double-stranded (ds) DNA anti-idiotypic antibodies obtained from a commercial IVIG in the treatment of experimental systemic lupus erythematosus (SLE). Specific natural polyclonal anti-dsDNA anti-idiotypic antibodies (IVIG-ID) were affinity purified from IVIG on an anti-dsDNA–Sepharose column constructed from anti-dsDNA idiotypes (ID) affinity purified from 55 patients with active SLE. NZB/W F1 mice were treated i.v. with 3 weekly injections of IVIG-ID (2 mg/kg/injection) or regular IVIG (400 mg/kg/injection) both before (age 8 weeks) and after developing anti-dsDNA antibodies at the age of 21–22 weeks. The IVIG-ID-treated mice showed a decline in the titer of anti-dsDNA antibodies during the treatment, reaching maximum suppression 1 week after the last injection. A significant difference in the proteinuria level in the IVIG-ID-treated group compared to the control group was observed. Immunohistology showed different patterns of IgG deposition, with mesangial and capillary wall deposits in controls and in the IVIG-treated group, but only mesangial deposits in the IVIG-ID-treated group. The survival time of the IVIG-ID-treated group was longer than the IVIG-treated group. Treatment with concentrated specific anti-dsDNA anti-ID prepared from commercial IVIG is more effective in suppressing the humoral reaction and clinical signs of SLE than native IVIG. These results point to the considerable regulatory role of anti-ID in the mechanism of action of IVIG in SLE.

Keywords: anti-DNA, anti-idiotype, i.v. Ig, NZB/W F1 mice, systemic lupus erythematosus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int ImmunolHome page
N. Dussault, E. Ducas, C. Racine, A. Jacques, I. Pare, S. Cote, and S. Neron
Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2
Int. Immunol., November 1, 2008; 20(11): 1369 - 1379.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. Perricone, C. De Carolis, B. Kroegler, E. Greco, R. Giacomelli, P. Cipriani, L. Fontana, and C. Perricone
Comment on: Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion: reply
Rheumatology, September 1, 2008; 47(9): 1439 - 1440.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. Perricone, C. De Carolis, B. Kroegler, E. Greco, R. Giacomelli, P. Cipriani, L. Fontana, and C. Perricone
Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion
Rheumatology, May 1, 2008; 47(5): 646 - 651.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Kessel, H. Ammuri, R. Peri, E. R. Pavlotzky, M. Blank, Y. Shoenfeld, and E. Toubi
Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function
J. Immunol., October 15, 2007; 179(8): 5571 - 5575.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. Blank, L. Anafi, G. Zandman-Goddard, I. Krause, S. Goldman, E. Shalev, R. Cervera, J. Font, M. Fridkin, H.-J. Thiesen, et al.
The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model
Int. Immunol., July 1, 2007; 19(7): 857 - 865.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Y. Shoenfeld, R. Wu, L. D. Dearing, and E. Matsuura
Are Anti-Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective?
Circulation, October 26, 2004; 110(17): 2552 - 2558.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.